01Context before scoring
Life stage and cycle context
Cycle pattern, postpartum history, perimenopause, menopause, and other life-stage details need their own language and review rules.
CoreSignal Women · Coming soon
Women’s health deservesits own context system.
Life stage, cycle pattern, symptoms, fertility intent, medications, and treatment context cannot be responsibly reduced to a recolored men’s score.
CoreSignal Women is not launched · Waitlist only · No live Women score · No clinical functionality active
CoreSignal WomenContext before scoring
Coming soonWhat changedSymptoms and goals
Life stage
Cycle context
Fertility intent
Treatment timing
Clinical reviewActive
Safety behaviorNot yet verified
Live scoringOff
01
Built separatelyNot a recolored Men product.
02
Reviewed separatelyWomen-specific logic and language.
03
Safety before scoringHolds and failure modes first.
04
Released after proofNo silent activation.
What the product is being built to understand
The context around the symptom matters.
The same complaint can sit inside a very different record depending on life stage, cycle pattern, fertility intent, medications, treatment timing, and recent change.
02Patterns, not assumptions
Symptoms and changing patterns
The product is being designed to organize what changed, when it changed, and what else was happening at the same time.
03Intent stays attached
Fertility intent and treatment context
Fertility goals, contraception, medications, hormone treatment, and timing must remain visible when the record is reviewed.
04Safety before release
Safety holds and clinical review
Pregnancy-related behavior, clinical holds, escalation language, and release boundaries require separate verification before scoring is active.
One symptom, different surrounding context
“Fatigue” is not a complete record.
CoreSignal Women is being designed to organize the surrounding facts without turning them into a diagnosis. A licensed clinician decides what they mean.
Patient-reported changePersistent fatigueIllustrative context map
What the product may saySeveral context changes overlap. Review the record with a licensed clinician.
The release standard
Built separately. Reviewed separately. Released deliberately.
A waitlist is not a launch. Functionality remains off until the clinical, safety, governance, and release gates are complete.
01
Complete
Product research
Define the context, use cases, language, and boundaries the product must support.
02
Active
Women-specific clinical review
Review logic, terminology, life-stage context, and the limits of what the product may say.
03
Next gate
Safety behavior
Verify clinical holds, pregnancy-sensitive behavior, escalation language, and failure modes.
04
Not released
Verified release
Release only after independent review, protected CI, and controlled launch evidence are complete.
What exists today
A clear boundary between interest and availability.
Product updates and parent-brand education.
- Join the CoreSignal Women update list
- Review the product direction and release standard
- Explore the parent CoreSignal context system
Women intake, scoring, clinical functionality, and mobile release.
- No Women score is generated
- No clinical or pregnancy-sensitive workflow is active
- No environment switch can silently enable the product
Why the boundary matters
A polished interface cannot substitute for women-specific review.
- Life-stage and fertility context need dedicated logic
- Safety holds must be verified before scoring
- Language must be reviewed for what it implies
What remains clinical
Diagnosis, testing, prescribing, and treatment decisions.
- CoreSignal will not replace licensed clinical care
- It will not create treatment or dosing protocols
- It will not be used for urgent symptoms or emergencies
Before joining the list
What is—and is not—available today.
CoreSignal Women remains a future product. The waitlist is for updates only, and the release boundary stays visible on purpose.
01Is CoreSignal Women available now?
No. CoreSignal Women is in development. There is no live Women intake, score, clinical functionality, or mobile release. The current page is a product-status and waitlist surface only.
02Why not adapt the Men’s Optimization Index?
Women-specific life-stage context, cycle patterns, fertility intent, pregnancy-sensitive behavior, terminology, and safety rules require a separately reviewed product. Reusing the Men logic would create the appearance of completeness without the required clinical foundation.
03What happens when I join the waitlist?
You receive future-product updates. Joining does not activate a Women intake or score, enroll you in the Men pilot, or create a clinical relationship.
04Will the future product diagnose or recommend treatment?
No. The CoreSignal product boundary remains educational and organizational. Diagnosis, prescribing, dosing, and treatment decisions stay with licensed clinicians.
05What is being reviewed before release?
Women-specific logic and language, life-stage context, fertility and treatment interactions, pregnancy-sensitive behavior, clinical holds, failure modes, repository governance, and release controls all require review before functionality is activated.
06How is waitlist privacy handled?
The waitlist should collect only the minimum information needed for product updates. Do not submit symptoms, lab results, diagnoses, or other protected health information through the waitlist form.